New hope for hard-to-treat blood cancers: experimental drug CPI-613 tested

NCT ID NCT03793140

First seen Apr 01, 2026 · Last updated Apr 30, 2026 · Updated 7 times

Summary

This study tests the drug CPI-613 in people with Burkitt lymphoma/leukemia or high-grade B-cell lymphoma that has come back or not responded to prior treatment. About 24 participants aged 12 and older will receive the drug to see if it can shrink or control their cancer. The goal is to measure how many patients have a complete or partial response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • City of Hope

    Duarte, California, 91010, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • Md Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Memorial Sloan Kettering Basking Ridge

    Basking Ridge, New Jersey, 07920, United States

  • Memorial Sloan Kettering Bergen

    Montvale, New Jersey, 07645, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Commack

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Monmouth

    Middletown, New Jersey, 07748, United States

  • Memorial Sloan Kettering Nassau

    Uniondale, New York, 11553, United States

  • Memorial Sloan Kettering Westchester

    Harrison, New York, 10604, United States

  • University of Pennsylvania (Data Collection Only)

    Philadelphia, Pennsylvania, 19104, United States

Conditions

Explore the condition pages connected to this study.